| Name | Title | Contact Details |
|---|
RxWiki Inc. is a rapidly growing Digital Health company connecting pharmacies and patients through its Digital Pharmacist (www.digitalpharmacist.com) SaaS platform and original Pharmacist written and verified content. RxWiki`s Digital Pharmacist platform powers the websites and mobile applications of 1,300 specialty and community pharmacy brands. Patients can manage their medications, complete digital refills and engage with medication adherence programs. RxWiki`s original Pharmacist written and verified content includes 20,000 original health articles, 7,500 health-related videos, and 100 disease condition channels. More than 3,700 community pharmacies and national health brands, like Health Mart and Health Media Network, license this content to engage and educate their patients. The company is headquartered in Austin, Texas.
Body Logic is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radiancy, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Orangeburg, NY. To find more information about Radiancy, Inc., please visit www.radiancy.com
RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic